Literature DB >> 15542674

Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.

Karina Dalsgaard Sørensen1, Leticia Quintanilla-Martinez, Sandra Kunder, Jörg Schmidt, Finn Skou Pedersen.   

Abstract

SL3-3 murine leukemia virus is a potent inducer of T-lymphomas in mice. Using inbred NMRI mice, it was previously reported that a mutant of SL3-3 with all enhancer Runx (AML1/core) sites disrupted by 3-bp mutations (SL3-3dm) induces predominantly non-T-cell tumors with severely extended latency (S. Ethelberg, J. Lovmand, J. Schmidt, A. Luz, and F. S. Pedersen, J. Virol. 71:7273-7280, 1997). By use of three-color flow cytometry and molecular and histopathological analyses, we have now performed a detailed phenotypic characterization of SL3-3- and SL3-3dm-induced tumors in this mouse strain. All wild-type induced tumors had clonal T-cell receptor beta rearrangements, and the vast majority were CD3(+) CD4(+) CD8(-) T-lymphomas. Such a consistent phenotypic pattern is unusual for murine leukemia virus-induced T-lymphomas. The mutant virus induced malignancies of four distinct hematopoietic lineages: myeloid, T lymphoid, B lymphoid, and erythroid. The most common disease was myeloid leukemia with maturation. Thus, mutation of all Runx motifs in the enhancer of SL3-3 severely impedes viral T-lymphomagenicity and thereby discloses a considerable and formerly unappreciated potential of this virus for myeloid leukemia induction. Proviral enhancers with complex structural alterations (deletions, insertions, and/or duplications) were found in most SL3-3dm-induced T-lymphoid tumors and immature myeloid leukemias but not in any cases of myeloid leukemia with maturation, mature B-lymphoma, or erythroleukemia. Altogether, our results indicate that the SL3-3dm enhancer in itself promotes induction of myeloid leukemia with maturation but that structural changes may arise in vivo and redirect viral disease specificity to induction of T-lymphoid or immature myeloid leukemias, which typically develop with moderately shorter latencies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542674      PMCID: PMC524987          DOI: 10.1128/JVI.78.23.13216-13231.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.

Authors:  A L Zaiman; J Lenz
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

2.  Flow cytometric identification of murine neutrophils and monocytes.

Authors:  E Lagasse; I L Weissman
Journal:  J Immunol Methods       Date:  1996-10-16       Impact factor: 2.303

Review 3.  Molecular analysis and characterization of two myeloid leukemia inducing murine retroviruses.

Authors:  E Rassart; J Houde; C Denicourt; M Ru; C Barat; E Edouard; L Poliquin; D Bergeron
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

4.  AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization.

Authors:  D Levanon; V Negreanu; Y Bernstein; I Bar-Am; L Avivi; Y Groner
Journal:  Genomics       Date:  1994-09-15       Impact factor: 5.736

5.  Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.

Authors:  A L Zaiman; A F Lewis; B E Crute; N A Speck; J Lenz
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Biological characterization and molecular cloning of murine C-type retroviruses derived from the TSZ complex from mainland China.

Authors:  L M Bundy; M Ru; B F Zheng; L Cheng; P K Pattengale; J L Portis; H Fan
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

7.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

8.  Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.

Authors:  H L Morrison; B Soni; J Lenz
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

9.  CD43 (S7) expression identifies peripheral B cell subsets.

Authors:  S M Wells; A B Kantor; A M Stall
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

10.  Transplantable NK cell progenitors in murine bone marrow.

Authors:  T Moore; M Bennett; V Kumar
Journal:  J Immunol       Date:  1995-02-15       Impact factor: 5.422

View more
  14 in total

1.  The myeloid features of BXH2 leukemias may result from the lack of one copy of the repetitive sequence in the long terminal repeat viral enhancer.

Authors:  Liqun Huang; Motomi Osato; Masatoshi Yanagida; Namiko Yamashita; Yoshiaki Ito
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

2.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

3.  A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus.

Authors:  Sys Zoffmann Glud; Annette Balle Sørensen; Mindaugas Andrulis; Bruce Wang; Eisaku Kondo; Randi Jessen; Laszlo Krenacs; Eva Stelkovics; Matthias Wabl; Edgar Serfling; Alois Palmetshofer; Finn Skou Pedersen
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

4.  Activation of an oncogenic microRNA cistron by provirus integration.

Authors:  Clifford L Wang; Bruce B Wang; Gábor Bartha; Lauri Li; Namitha Channa; Mark Klinger; Nigel Killeen; Matthias Wabl
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-22       Impact factor: 11.205

5.  Importance of receptor usage, Fli1 activation, and mouse strain for the stem cell specificity of 10A1 murine leukemia virus leukemogenicity.

Authors:  Michaela Rodenburg; Meike Fischer; Afra Engelmann; Stephanie O Harbers; Marion Ziegler; Jürgen Löhler; Carol Stocking
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

7.  Activation of the brain-specific neurogranin gene in murine T-cell lymphomas by proviral insertional mutagenesis.

Authors:  Anne Ahlmann Nielsen; Kristín Rós Kjartansdóttir; Mads Heilskov Rasmussen; Annette Balle Sørensen; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Gene       Date:  2009-04-17       Impact factor: 3.688

8.  Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes.

Authors:  Magdalena Julia Dabrowska; Ditte Ejegod; Louise Berkhoudt Lassen; Hans Erik Johnsen; Matthias Wabl; Finn Skou Pedersen; Karen Dybkær
Journal:  Leuk Res       Date:  2013-07-26       Impact factor: 3.156

9.  Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1.

Authors:  Magdalena Julia Dabrowska; Karen Dybkaer; Hans Erik Johnsen; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

10.  Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia.

Authors:  Kiriko Kaneko; Kazumichi Furuyama; Tohru Fujiwara; Ryoji Kobayashi; Hiroyuki Ishida; Hideo Harigae; Shigeki Shibahara
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.